Philips' profits jump thanks to cost cuts; St. Jude launches stent-placement tech;

@FierceMedDev: New special report: Top Med Tech Investments of Q3. Report | Follow @FierceMedDev

@MarkHFierce: For Boston Scientific, the first vaginal mesh implant lawsuits are slated to begin in March. Will the company settle? Item | Follow @MarkHFierce

@MichaelGFierce: Implantable, light-sensitive hydrogel could help treat diabetes. More from FierceDrugDelivery | Follow @MichaelGFierce

> Philips Healthcare ($PHG) said its profits jumped nearly 8% last quarter, even though sales dipped. The division makes everything from mobile scanners to high-end medical imaging equipment. Story

> Illumina ($ILMN) has launched its TruGenome Undiagnosed Disease Test, a system that uses whole human genome sequencing to help physicians identify the underlying genetic causes of ailments. More

> With FDA approval in hand, St. Jude Medical ($STJ) is launching its new Ilumien Optis PCI Optimization System, technology designed to help treat coronary artery disease by modeling vessels and guiding stent placement. Item

> Sequenom ($SQNM) has expanded its MaterniT21 prenatal diagnostic to detect subchromosomal microdeletions. News

> Texas Children's Hospital and Baylor College of Medicine said they are part of a consortium that won a $1.5 million FDA grant to boost the development of pediatric medical devices. Item   

Biotech News

@FierceBiotech: ICYMI yesterday: 20 BigPharma and biotech mobile apps - 2013. Report | Follow @FierceBiotech

@JohnCFierce: Good thing we have archives--Pain surges after Pfizer commits to 3rd try for long-delayed pain drug Remoxy. Story | Follow @JohnCFierce

@DamianFierce: It's another Class I recall for CareFusion, and these things are starting to catch up with revenue, it seems. News | Follow @DamianFierce

> Novartis grabs an option to buy biotech startup for up to $300M. Story

> Gene therapy upstart launches with $50M and long-term commercial goals. More

> FDA gives J&J a thumbs-up--with a catch--on hep C drug simeprevir. Article

Pharma News

@FiercePharma: Two most popular profiles from our Top 10 generics makers report: Teva and Sandoz | Follow @FiercePharma

@CarlyHFierce: Check out the top 10 DTC pharma advertisers from 2013 H1 in the new report. | Follow @CarlyHFierce

> Report: Feds get big 'bang for the buck' in fighting pharma fraud. Story

> Still free from Diovan rivals, Novartis hikes forecast once again. Report

Biotech Research News

@EmilyMFierce:  | Follow @EmilyMFierce

> Harvard, AstraZeneca partner to replace animal testing with 'organs-on-chips.' More

> Takeda, Hopkins developing new pancreatic cancer drugs. Story

> Novartis CDK 4/6 cancer drug effective in preclincal tests, advances to PhI. Item

> New approach could lead to universal flu vaccine. Article

> Mini pancreas grown in lab using mouse cells. Story

Pharma Manufacturing News

@EricPFierce: Is there a connection between pharma DTC spending and job cuts? In some cases, yes. FiercePharma special report | Follow @EricPFierce

> U.K. takes enforcement action against third Wockhardt plant. More

> Authorities seize large load of fake Xanax headed for Egypt. Story

> Teva API plant workers strike over wage gaps. Article

> German contract manufacturers invest €70 million on expansions. Item

> Teva opens $100M Croatia plant as it cuts elsewhere. Report

> Biocad taking biosimilar production to Brazil. More

BD&L Summit

Deal-Making Insights for the Life Sciences Industry

Bringing together key deal-makers and serving as an open forum for cross-functional business development and legal teams to share valuable insights and actionable strategies on successfully managing alliances, licensing agreements, and M&A deals.